rhenium (186Re) obisbemeda (REYOBIQ) — Interim data
Q4 2026
LM phase 2 interim analysis Q4 2026Source filing
CNSY biotech catalysts & pipeline
CERENOME INC · Data as of 2026-10-25
Upcoming catalysts
CNSide — Regulatory decision
Nov 2026
Medicare rate expected effective Jan 1, 2027; CMS final pricing expected November 2026Source filing
CNSide — Regulatory decision
Jan 1
Medicare rate expected effective Jan 1, 2027; CMS final pricing expected November 2026Source filing
GBM — Clinical data readout
1H 2027
GBM phase 2 read out 1H 2027Source filing
rhenium (186Re) obisbemeda (REYOBIQ) — Clinical data readout
Q1 2027
Complete enrollment in the ReSPECT-GBM Phase 2 trial for glioblastoma; data is expected in Q1 2027, followed by an End-of-Phase 2 meeting with the FDASource filing